diversified growth Gubra operates across three synergistic units—Biotech, CRO Services, and Ventures—providing multiple touchpoints for revenue opportunities, from proprietary therapeutics to high-end preclinical services and early-stage ventures.

metabolic focus Strong emphasis on metabolic diseases with lead obesity programs and partnerships (ABBV-295, BI 3034701) plus a clinical-stage internal candidate (GUB-UCN2) open doors for collaborative development, licensing, and co-development discussions.

ESG edge Gubra Green allocates 10% of pre-tax profits to net-zero and nature-positive initiatives, presenting a sustainability differentiator that can attract mission-aligned partners, grant funding, and responsible procurement conversations.

advanced capabilities World-class preclinical CRO offerings span in vivo pharmacology, ex vivo assays, peptide chemistry, AI-enhanced imaging, and bioinformatics, enabling cross-selling of services to biotech and pharma clients seeking translational accuracy.

scalable partnerships Ventures unit structures support rapid progression of high-potential programs with translational hypotheses, creating opportunities for strategic collaborations, licensing deals, and early-stage co-funding with industry players seeking agile biotech ventures.